Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal cell carcinoma (ccRCC): Primary endpoint met: Sensitivity of 84% and specificity of 84% in all three readers (86% / 87% overall) Considerably exceeds confirmatory trial sensitivity and specificity success targets Key secondary endpoints met, achieving 85% sensitivity and 89% specificity in small renal masses (cT1a 4cm) Full data set: 93% positive predictive val...